TY - JOUR
AU - Goyal, Ashish
AU - Bauer, Jens
AU - Hey, Joschka
AU - Papageorgiou, Dimitris N
AU - Stepanova, Ekaterina
AU - Daskalakis, Michael
AU - Scheid, Jonas
AU - Dubbelaar, Marissa
AU - Klimovich, Boris
AU - Schwarz, Dominic
AU - Märklin, Melanie
AU - Roerden, Malte
AU - Lin, Yu-Yu
AU - Ma, Tobias
AU - Mücke, Oliver
AU - Rammensee, Hans-Georg
AU - Lübbert, Michael
AU - Loayza-Puch, Fabricio
AU - Krijgsveld, Jeroen
AU - Walz, Juliane
AU - Plass, Christoph
TI - DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts.
JO - Nature Communications
VL - 14
IS - 1
SN - 2041-1723
CY - [London]
PB - Nature Publishing Group UK
M1 - DKFZ-2023-02154
SP - 6731
PY - 2023
N1 - #EA:B370#LA:B370#
AB - Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of cancer patients. Recent evidence suggests that epigenetic therapies synergize with immunotherapies, mediated by the de-repression of endogenous retroviral element (ERV)-encoded promoters, and the initiation of transcription. Here, we use deep RNA sequencing from cancer cell lines treated with DNA methyltransferase inhibitor (DNMTi) and/or Histone deacetylase inhibitor (HDACi), to assemble a de novo transcriptome and identify several thousand ERV-derived, treatment-induced novel polyadenylated transcripts (TINPATs). Using immunopeptidomics, we demonstrate the human leukocyte antigen (HLA) presentation of 45 spectra-validated treatment-induced neopeptides (t-neopeptides) arising from TINPATs. We illustrate the potential of the identified t-neopeptides to elicit a T-cell response to effectively target cancer cells. We further verify the presence of t-neopeptides in AML patient samples after in vivo treatment with the DNMT inhibitor Decitabine. Our findings highlight the potential of ERV-derived neoantigens in epigenetic and immune therapies.
LB - PUB:(DE-HGF)16
C6 - pmid:37872136
DO - DOI:10.1038/s41467-023-42417-w
UR - https://inrepo02.dkfz.de/record/284956
ER -